Orexo AB on Thursday said it is appealing part of a Delaware district court decision that found a patent for its opioid-treatment drug Zubsolv was invalid.
December 08, 2016 at 06:39 PM
1 minute read
Orexo AB on Thursday said it is appealing part of a Delaware district court decision that found a patent for its opioid-treatment drug Zubsolv was invalid.
The announcement came just one day after the Swedish pharmaceutical company and a U.S. affiliate sued Actavis Elizabeth for infringing another patent for the drug, which was not a part of the earlier lawsuit.
Presented by BigVoodoo
This event shines a spotlight on the individuals, teams, projects and organizations that are changing the financial industry.
BTI provides leading tax professionals from financial institutions with unmatched tools and resources.
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
CORE RESPONSIBILITIES AND TASKS:(1) Tasks and responsibilities include:Reviewing and negotiating commercial agreements for internal business...
Boutique midtown Manhattan law firm specializing in sophisticated real estate litigation & representation of commercial and residential ...
Description: Fox Rothschild has an opening in the Boston, MA office for a Litigation Associate with 3 to 5 years of experience. The ideal ca...
